References
- Chandraratna R. (1996). Tazarotene – first of a new generation of receptor-selective retinoids. Br J Dermatol 135:18–25
- Chuang T-Y, Samson C. (1991). Clinical efficacy and safety of augmented betamethasone dipropionate ointment and diflorasone diacetate ointment for psoriasis – a multicentre, randomized, double-blinded study. J Dermatol Treat 2:63–6
- De Iudicibus S, Franca R, Martelossi S, et al. (2011). Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol 17:1095–1108
- De Vries F, Pouwels S, Lammers J, et al. (2007). Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case–control study. J Intern Med 261:170–7
- Diane D-S, Matsumoto RM, Usansky JI. (1999). Clinical pharmacokinetics and drug metabolism of tazarotene. Clin Pharmacokinet 37:273–87
- Finlay A, Coles E. (1995). The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 132:236–44
- Greaves MW, Weinstein G. (1995). Treatment of psoriasis. N Engl J Med 332:581–8
- Green L, Sadoff W. (2002). A clinical evaluation of tazarotene 0.1% gel, with and without a high-or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 6:95–102
- Guenther LC. (2003). Optimizing treatment with topical tazarotene. Am J Clin Dermatol 4:197–202
- Jacobi U, Weigmann HJ, Ulrich J, et al. (2005). Estimation of the relative stratum corneum amount removed by tape stripping. Skin Res Technol 11:91–6
- Jin Y, Xiao-Quan L, Xiao-Dong L. (2003). Development of bioavailability program package 2.0. Chinese J Clin Pharmacol 19:125–7
- Kaufmann R, Bibby A, Bissonnette R, et al. (2002). A new calcipotriol/betamethasone dipropionate formulation (DaivobetTM) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 205:389–93
- Koo JY, Martin D. (2001). Investigator-masked comparison of tazarotene gel qd plus mometasone furoate cream qd vs. mometasone furoate cream bid in the treatment of plaque psoriasis. Int J Dermatol 40:210–12
- Lebwohl M, Ast E, Callen JP, et al. (1998a). Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 38:705–11
- Lebwohl MG, Breneman DL, Goffe BS, et al. (1998b). Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 39:590–6
- Man X-Y, Li W, Chen J-Q, et al. (2013). Impaired nuclear translocation of glucocorticoid receptors: novel findings from psoriatic epidermal keratinocytes. Cell Mol Life Sci 70:2205–20
- Menter A. (2000). Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 43:S31–5
- Nevitt G, Hutchinson P. (1996). Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 135:533–7
- Ohnishi T, Sher PB, Posner JB, Shapiro WR. (1990). Capillary permeability factor secreted by malignant brain tumor: role in peritumoral brain edema and possible mechanism for anti-edema effect of glucocorticoids. J Neurosurg 72:245–51
- Poulin Y. (1999). Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis 63:41–8
- Prusakiewicz JJ, Ackermann C, Voorman R. (2006). Comparison of skin esterase activities from different species. Pharmaceut Res 23:1517–24
- Roberts D. (1996). Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17, 21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Cutis 57:27–31
- Shupack J, Jondreau L, Kenny C, Stiller M. (1993). Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate-severe plaque-type psoriasis. Dermatology 186:129–32
- Souverein P, Berard A, Van Staa T, et al. (2004). Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart 90:859–65
- Tanghetti E. (2000). An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis 66:4–11
- Vegiopoulos A, Herzig S. (2007). Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocr 275:43–61
- Watts SW, Dorrance AM, Penfold ME, et al. (2013). Chemerin connects fat to arterial contraction. Arterioscler Thromb Vasc Biol 33:1320–8